Dyadic International, Inc. filings document the regulatory disclosures of a Nasdaq-listed biotechnology company developing and commercializing recombinant proteins and enzymes through proprietary microbial expression platforms. Form 8-K reports cover financial results, press-release exhibits, business-development updates, and Nasdaq continued-listing matters affecting the company's common stock.
The filing record also includes material agreements and capital-structure disclosures, including equity issuance programs under shelf registration statements, underwriting arrangements for common stock offerings, and amendments to security agreements tied to senior secured convertible promissory notes. These documents describe Dyadic's governance, registered securities, financing activity, listing compliance, and formal event reporting.
Dyadic International Inc. is the issuer whose common stock is the subject of a reported position of 3,346,275 shares, or 8.35%, attributed to Empery Asset Management, LP, the investment manager to the Empery Funds, and Ryan M. Lane, identified as the reporting individual. Both report shared voting and shared dispositive power over 3,346,275 shares, with no sole voting or dispositive power. The percentage is based on 40,063,703 shares outstanding as of September 10, 2026. The Empery Funds and Ryan M. Lane disclaim beneficial ownership.
Dyadic International, Inc. (DYAI) received two Nasdaq deficiency notices on September 25, 2026, after its common stock failed to maintain the minimum bid-price and market-value requirements for 30 consecutive business days. One notice cites the minimum bid price of $1 per share; the other cites the $35 million minimum Market Value of Listed Securities. The notices have no immediate effect on the company’s Nasdaq Capital Market listing.
Dyadic has until March 24, 2027, to meet each test: a closing bid price of at least $1 per share and a closing market value of at least $35 million, each for a minimum of 10 consecutive business days. For the bid-price deficiency, it may be eligible for an additional 180-day period if it meets other listing conditions and gives Nasdaq written notice of its intent to cure, by effecting a reverse stock split if necessary. Failure to regain compliance can lead to delisting notifications, which the company may appeal. Dyadic plans to monitor both measures and evaluate options.
Dyadic International, Inc. (DYAI) is registering up to 3,625,000 shares of common stock for resale by existing holders, issuable upon exercise of warrants with an exercise price of $0.84 per share. These are secondary sales; Dyadic is not selling any shares in this offering.
The selling stockholders may dispose of shares from time to time at market or negotiated prices using various methods, including brokered and privately negotiated transactions. Dyadic will receive cash only if the warrants are exercised, and any resale proceeds will go solely to the selling stockholders.
Dyadic International, Inc. (DYAI) is registering the resale by selling stockholders of up to 3,625,000 shares of common stock issuable upon exercise of outstanding warrants with an exercise price of $0.84 per share. The company is not selling any shares in this offering and will receive cash only if the warrants are exercised. Shares may be sold from time to time by the selling stockholders at market or negotiated prices through various methods of distribution. Common stock outstanding was 40,063,703 shares as of September 10, 2026, and would be 43,688,703 shares if all registered warrants are exercised. Dyadic describes itself as a smaller reporting company focused on microbial expression platforms for recombinant proteins across life sciences, food, nutrition and industrial markets.
Dyadic International Inc. investor Francisco Trust under agreement dated February 28, 1996 reports beneficial ownership of 4,232,653 shares of Dyadic common stock, representing 10.32% of the class. This includes 3,280,272 shares currently held and 952,381 shares issuable upon conversion of a convertible promissory note dated March 8, 2024, as amended, at a conversion price of $1.05 per share. Based on 40,063,703 Dyadic common shares outstanding as of August 14, 2026, the trust has sole voting and dispositive power over all 4,232,653 shares.
Dyadic International, Inc. entered into agreements for a capital raise combining a registered direct stock sale and a concurrent private placement of warrants. The company agreed to sell 3,625,000 shares of common stock at $0.795 per share under an effective Form S-3 shelf registration and to issue Common Warrants to purchase 3,625,000 shares at an exercise price of $0.84 per share, priced at $0.005 per warrant. Closing is expected on or about August 14, 2026, subject to customary conditions.
Aggregate gross proceeds are expected to be about $2.9 million, to be used for general corporate purposes including R&D, sales and marketing, administrative expenses, working capital, capital expenditures, and potential acquisitions or strategic transactions. The warrant offering is being conducted as a private placement under Section 4(a)(2) and Rule 506, with a Registration Rights Agreement requiring Dyadic to file a resale registration statement for the warrant shares within 30 days after closing. A placement agent agreement with Aegis Capital Corp. covers the offerings, and Dyadic and key stakeholders are subject to 90-day standstill and lock-up restrictions after the defined Release Date.
Dyadic International, Inc. is conducting a registered direct primary offering of 3,625,000 shares of common stock at $0.795 per share, for gross proceeds of $2,881,875. Aegis Capital Corp. acts as placement agent on a reasonable best efforts basis and receives a 7% cash fee.
Concurrently, Dyadic will sell in a private placement warrants to purchase 3,625,000 shares at an exercise price of $0.84, at $0.005 per warrant. Each closing is contingent on the other. After placement fees and estimated expenses, Dyadic expects net proceeds of approximately $2.28 million, to be used for general corporate purposes including R&D, sales and marketing, working capital, capital expenditures, and potential acquisitions.
Shares outstanding will increase from 36,438,703 to 40,063,703, and the company highlights immediate and substantial dilution of $0.80 per share to new investors based on its June 30, 2026 net tangible book deficit. Executives, directors, key holders, and the company are generally subject to 90-day lock-up and standstill provisions, and Aegis receives a nine‑month right of first refusal on certain future financings.
Dyadic International, Inc. reported second-quarter 2026 results showing a small revenue increase but continued significant losses and liquidity pressure. Total revenue for the six months ended June 30, 2026 was $2,072,094, up from $1,360,202 a year earlier, driven mainly by grant revenue and collaboration work. However, net loss for the six months was $4,078,567, only slightly higher than the prior-year loss of $3,821,353, as operating expenses remained well above revenue.
As of June 30, 2026, Dyadic held $4.8 million in cash, cash equivalents, restricted cash and investment securities and reported stockholders’ deficit of $2,387,244, compared with positive equity at year-end 2025. Management states there is substantial doubt about the company’s ability to continue as a going concern over the next 12 months, citing recurring losses, negative operating cash flow of $3,781,366 in the first half, and a long-term accumulated deficit of $97,529,675.
The company is rebranding as Dyadic Applied BioSolutions and shifting focus toward commercializing non-therapeutic protein products using its Dapibus™ and C1 platforms. It relies heavily on external funding, including a $3,092,136 Gates Foundation grant, up to $2,432,756 from a CEPI-related grant, $5.09 million of 8% Senior Secured Convertible Notes outstanding, and a $4,238,000 at-the-market equity program that had not been utilized by the report date.
Dyadic International reported second-quarter 2026 results, combining growing commercial activity with mounting financial pressure. Total revenue was $961,138 for the quarter ended June 30, 2026, slightly below $966,630 a year earlier, as higher grant revenue of $837,252 offset lower research and development and milestone revenue. Cost of revenue rose to $984,165, driven mainly by CEPI and Gates Foundation grant activity, resulting in a negative gross margin.
Operating expenses shifted, with research and development expenses reduced to $332,621 from $629,379, while general and administrative costs increased to $1,689,863, reflecting rebranding, business development, legal and accounting spending. Loss from operations widened to $2,054,204, and net loss was $2,123,884, or $(0.06) per share, compared with $1,793,774, or $(0.06) per share, a year earlier.
Liquidity and balance sheet indicators weakened. As of June 30, 2026, cash, cash equivalents, restricted cash and investment-grade securities totaled $4,794,798, down from $8,587,289 as of December 31, 2025. Total assets were $6,536,531 against total liabilities of $8,923,775, and stockholders’ equity moved to a deficit of $(2,387,244). The company states management has concluded there is substantial doubt about its ability to continue as a going concern for the 12 months following June 30, 2026, and notes potential dilutive capital raises as a risk. Dyadic also highlights progress in commercial shipments, OEM distribution, precision-fermented dairy partnerships, and global health collaborations using its C1 expression system.